 |
(top) MHC class I molecules display peptides processed from intracellular proteins, presenting this complex to T-Cell Receptors. Recognition of non-self peptide antigens stimulates the cellular immune system to eliminate the diseased cell.
(bottom) T-Cell Receptor mimics (TCRm’s) exhibit similar binding affinity to CTLs (‹150 pM), and as a soluble reagent serve to augment traditional cell-based binding assays. |
Receptor Logic – Immunology On Target
Receptor Logic, Inc. is a life science company providing powerful tools for medical research, diagnostics, and treatment of diseases such as cancer. Our knowledge of the underlying science of the immune system has led to the groundbreaking discovery and development of T Cell Receptor mimic (TCRm) technology – a specialized monoclonal antibody for use in disease research, vaccine development, and treatment of cancer.
TCRm technology is a breakthrough technology that allows the precise detection of biomarkers presented on diseased, infected or cancerous cells. TCRm monoclonal antibodies can be integrated into a number of existing assays providing a quantitative baseline for historically poorly quantitative assays involving T-cell function. Further, the potency of vaccines or active immunotherapies can be effectively measured by TCRm antibodies. The impressive specificity of TCRm antibodies coupled with their ability to recognize validated disease biomarkers make them ideal immunological tools for cancer and infectious disease detection and treatment. TCRm applications include:
Reagents for immunology research
Potency assay services
Therapeutic and diagnostic monoclonal antibodies
|
Applications and Literature
HLA-omics and cancer biomarkers: emerging tools and technologies for the medical laboratory
Receptor Logic Teams With Sanofi Pasteur To Develop T Cell Receptor Mimics (TCRm™) for Vaccine Research
Receptor Logic Quarterly Update-Winter 2008
Antibody Targeting to Class I MHC-peptide Epitope Promotes Tumor Cell Death
Direct Epitope Validation Using Monoclonal TCR Mimic Antibodies
Levels of Specific Peptide-HLA Class I Complex Determines Tumor Cell Susceptibility to CTL Killing
|
